Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

Title
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Author(s)
원규장Y.Seino[Y.Seino]K.W. Min[K.W. Min]E. Niemoeller[E. Niemoeller]A. Takami[A. Takami]박홍선[박홍선]장학철[장학철]김인주[김인주]김광원[김광원]이현철[이현철]이관우[이관우]
Keywords
PEPTIDE-1 ANALOG LIRAGLUTIDE; JAPANESE PATIENTS; GLYCEMIC CONTROL; SAFETY; EXENATIDE; EFFICACY; METFORMIN; HYPERGLYCEMIA; WEIGHT; GLIBENCLAMIDE
Issue Date
201210
Publisher
WILEY-BLACKWELL
Citation
DIABETES OBESITY & METABOLISM, v.14, no.10, pp.910 - 917
Abstract
Aims: To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin +/- sulfonylurea. Methods: In this 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicentre study, participants (mean baseline HbA(1c) 8.53%) from Japan, Republic of Korea, Taiwan and the Philippines received lixisenatide (n=154) or placebo (n=157) in a stepwise dose increase to 20 mu g once daily. The primary endpoint was HbA(1c) change from baseline to week 24. Results: Once-daily lixisenatide significantly improved HbA(1c) versus placebo (LS mean difference vs. placebo=-0.88% [95% CI=-1.116, -0.650]; p<0.0001), and allowed more patients to achieve HbA(1c) < 7.0% (35.6 vs. 5.2%) and <= 6.5% (17.8 vs. 1.3%). Lixisenatide also significantly improved 2-h postprandial plasma glucose and glucose excursion, average 7-point self-monitored blood glucose and fasting plasma glucose. Lixisenatide was well tolerated; 86% of patients on lixisenatide completed the study versus 92% on placebo. Ten (6.5%) lixisenatide and 9 (5.7%) placebo patients experienced serious adverse events. More lixisenatide patients [14 (9.1%)] discontinued for adverse events versus placebo [5 (3.2%)], mainly with gastrointestinal causes. Nausea and vomiting were reported in 39.6 and 18.2% of patients on lixisenatide versus 4.5 and 1.9% on placebo. Symptomatic hypoglycaemia was more frequent with lixisenatide (42.9%) versus placebo (23.6%), but was similar between groups (32.6 vs. 28.3%, respectively), in those not receiving sulfonylureas. No severe hypoglycaemia was reported. Conclusions: In an Asian type 2 diabetes population insufficiently controlled by basal insulin +/- sulfonylurea, once-daily lixisenatide significantly improved glycaemic control, with a pronounced postprandial effect, and was well tolerated.
URI
http://hdl.handle.net/YU.REPOSITORY/27092http://dx.doi.org/10.1111/j.1463-1326.2012.01618.x
ISSN
1462-8902
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE